17 reports

Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) - Drugs in Development, 2021 Summary Glutamate Carboxypeptidase 2 (Folate Hydrolase 1...

  • Vitamin
  • Research And Development
  • Drug Development
  • World

Cells Expressing Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) - Drugs in Development, 2021 Summary Cells Expressing Glutamate Carboxypeptidase...

  • Vitamin
  • Research And Development
  • Drug Development
  • World

Global Radioligand Therapy Market to Reach $16,658.4 Million by 2031 Market Report Coverage - Radioligand Therapy Market Segmentation • Product (Approved Products and Potential Pipeline) • Indication (Prostate Cancer, Neuroendocrine Tumor (NETs), and Others) • Biomarker (Prostate-Specific...

  • Therapy
  • World

Major players in the prostate cancer drugs market are Astellas Inc., AstraZeneca plc, Johnson & Johnson, Sanofi S.A, Bayer AG, Roche, Abbott, Pfizer, Norvaris and F. Hoffmann-La Roche AG. The global prostate cancer drugs market is expected to grow from $16.09 billion in 2021 to $17.64 billion in 2022 at a compound annual growth rate...

  • Prostate Cancer
  • World
  • United States
  • Drug Approval

PSMA (prostate-specific membrane antigen) DNA vaccine elicits anti-tumor properties.

  • Prostate Cancer
  • Pharmaceutical
  • Renal Cancer
  • World
  • Pharmaceutical Registrations

The Global Peptide Therapeutics Market size is expected to reach $58.4 billion by 2028, rising at a market growth of 6.3% CAGR during the forecast period. Peptide therapeutics are polypeptides or peptides (oligomers or short polymers of amino acids) that are utilized to treat disorders. Peptide treatments replicate natural peptide functions...

  • Therapy
  • World
  • Drug Approval
  • Cancer Mortality

Antibody Drug Conjugates Market Report 2021-2031: Forecasts by Technology (Cleavable Linkers, Non-Cleavable Linkers, Other Technology), by Payload Type (MMAE, DM4, Camptothecin, DM1, MMAF, Other Payload Type), by Target Antigen (CD30, HER2, CD22, CD33), by Drug Type (Adcetris, Kadcyla, Other Drugs), by Application (Blood Cancer, Breast...

  • Biopharmaceutical
  • World
  • APAC
  • Europe
  • Cancer Incidence

The Global Hybrid Imaging Market size is expected to reach $9.1 billion by 2025, rising at a market growth of 4.44% CAGR during the forecast period. Hybrid imaging is the fusion of more than two imaging technologies that form a new technique. The combinations of the innate benefits of the fused imaging technologies form a novel and much stronger...

  • Diagnostic Imaging
  • CT Scan
  • World
  • Medical Instrument And Supply Production

Summary Lantheus Medical Imaging Inc (Lantheus Medical), a subsidiary of Lantheus Holdings, Inc., develops, manufactures and commercializes diagnostic imaging agents and products. The company offers commercial products including ultrasound contrast agent and medical radiopharmaceuticals in a range of imaging modalities....

  • Diagnostic Imaging
  • World
  • United States
  • North America
  • Diagnostic Imaging Density
  • Practising Physicians

Summary Novartis AG (Novartis) is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products.It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders,...

  • Clinical Trial
  • Pulmonary Delivery
  • Europe
  • World
  • Switzerland
  • Western Europe
  • United States
  • North America
  • Medical Technology Density
  • Diagnostic Imaging Density

ImaginAb Extends Licensing Agreement With Bzl Biologics For Imaging Prostate Specific Membrane Antigen

  • Medical Equipment
  • Japan
  • Medical Devices Sales
  • Prescription Drug Sales

PSMA (prostate-specific membrane antigen) DNA vaccine elicits anti-tumor properties.

  • Prostate Cancer
  • Pharmaceutical
  • Renal Cancer
  • World

PSMA (prostate-specific membrane antigen) DNA vaccine elicits anti-tumor properties.

  • Prostate Cancer
  • Monoclonal Antibody
  • Chronic Pain
  • Pharmaceutical
  • Renal Cancer
  • World

• The global market for antibody drug conjugates was valued at $1.3 billion in 2016. The market should reach $4.2 billion by 2021, growing at a compound annual growth rate (CAGR) of 25.5% from 2016 to 2021. • North American market for antibody drug conjugates was valued at $588.6 million in 2016. The market should reach $2.0 billion...

  • Biopharmaceutical
  • Monoclonal Antibody
  • World
  • North America
  • APAC
  • Health Expenditure
  • Drug Approval

PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2026 Summary Prostate cancer (PCa) is the second most common cancer in men worldwide, after skin cancer. It accounts for 12% of all the cancers diagnosed in men, and thus represents a huge burden on healthcare systems....

  • Prostate Cancer
  • United States
  • Japan
  • World
  • Life Expectancy
  • Drug Approval

Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate...

  • Monoclonal Antibody
  • Vaccine
  • Vitamin
  • World
  • Pharmaceutical Production

Prostate cancer has emerged as a disease with one of the highest incidences and mortality rates in males across the world. This situation has created a large unmet medical demand for better therapeutics by patients suffering from prostate cancer due to modest response generated by presently available therapeutics. Hormone based therapeutics...

  • Prostate Cancer
  • World
  • Mortality Rate
  • Cancer Incidence